Merck & Company Inc (MRK)vsTscan Therapeutics Inc (TCRX)
MRK
Merck & Company Inc
$148.49
-0.78%
HEALTHCARE · Cap: $368.89B
TCRX
Tscan Therapeutics Inc
$0.18
+2.69%
HEALTHCARE · Cap: $12.86M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 947418% more annual revenue ($67.38B vs $7.11M). MRK leads profitability with a 3.6% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 44/100 (D).
MRK
Hold44
out of 100
Grade: D
TCRX
Avoid35
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-76.6%
Fair Value
$84.66
Current Price
$148.49
$63.83 premium
Intrinsic value data unavailable for TCRX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 41.2%
Generating 4.5B in free cash flow
Reasonable price relative to book value
Areas to Watch
Trading at 8.7x book value
4.7% revenue growth
ROE of 7.6% — below average capital efficiency
3.6% margin — thin
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : TCRX
The strongest argument for TCRX centers on Price/Book.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Revenue Growth, Return on Equity. A P/E of 151.0x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.
Bear Case : TCRX
The primary concerns for TCRX are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
TCRX carries more volatility with a beta of 1.14 — expect wider price swings.
MRK is growing revenue faster at 4.7% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MRK scores higher overall (44/100 vs 35/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Tscan Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Tscan Therapeutics Inc (TCRX) is a pioneering clinical-stage biotechnology company specializing in precision oncology through its proprietary T cell receptor (TCR) discovery platform. The firm is dedicated to developing a diverse pipeline of TCR-based therapeutics targeting specific cancer antigens, with the objective of enhancing patient outcomes across various malignancies. With a strong intellectual property portfolio and a strategic emphasis on T cell-based immunotherapies, Tscan is well-positioned to meet significant unmet medical needs in the oncology sector, standing out in a competitive and rapidly evolving market.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?